Kacie Orozco
Family · Victorville, CANPI 1306369376
Payments from drug & device makers
Across 87 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$306
- Johnson & Johnson$201
- Boston Scientific$156
- AstraZeneca$141
- Sanofi-aventis U.S. LLC$105
- Penumbra, Inc.$99
- plus $871 from 20 others
What the payments were for
- Food & beverage$1,879100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $306 |
| Johnson & Johnson(2 entities) | 10 | $201 |
| Boston Scientific | 6 | $156 |
| AstraZeneca | 8 | $141 |
| Sanofi-aventis U.S. LLC | 4 | $105 |
| Penumbra, Inc. | 2 | $99 |
| AbbVie | 4 | $90 |
| Pfizer | 3 | $66 |
| Amgen | 3 | $65 |
| Biotronik Inc. | 3 | $64 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $63 |
| Melinta Therapeutics, LLC | 2 | $60 |
| Novo Nordisk | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Viiv Healthcare Company | 2 | $49 |
| Shionogi Inc | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
| Gilead | 2 | $34 |
| Bayer | 2 | $31 |
| Abiomed | 1 | $31 |
| Edwards Lifesciences | 1 | $23 |
| Medtronic | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Exact Sciences | 1 | $17 |
| Novartis | 1 | $16 |
How this compares
$1,879 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 91 | $82,120 |
| EliquisApixaban | 85 | $68,952 |
| Daptomycin | 42 | $42,593 |
| FarxigaDapagliflozin Propanediol | 48 | $39,622 |
| JardianceEmpagliflozin | 50 | $32,975 |
| MultaqDronedarone Hcl | 17 | $15,628 |
| XareltoRivaroxaban | 18 | $12,252 |
| ErtapenemErtapenem Sodium | 14 | $8,122 |
| CeftriaxoneCeftriaxone Sodium | 43 | $5,172 |
| Atorvastatin Calcium | 155 | $784 |
| Metoprolol Succinate | 75 | $556 |
| ClopidogrelClopidogrel Bisulfate | 49 | $544 |
| Carvedilol | 153 | $497 |
| Warfarin Sodium | 30 | $376 |
| Amiodarone Hcl | 19 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $16 | $82,12091 claims |
| PfizerEliquis | $66 | $68,95285 claims |
| AstraZenecaFarxiga | $141 | $39,62248 claims |
| Sanofi-aventis U.S. LLCMultaq | $105 | $15,62817 claims |
| Johnson & JohnsonXarelto | $201 | $12,25218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.
Other family in Victorville
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.